Bacillus Thuringiensis Strain

Abstract

The invention provides a B. thuringiensis {Bt) strain which does not produce beta-exotoxin and which exhibits insecticidal activity against Spodoptera frugiperda, an insect whose control is poor or ineffective with the currently market available Bt-based products. Thus, compositions based in this strain can be used as insecticides or for preparation of insecticides, being preferably that the composition used is a combination of spores and crystal proteins of the strain. The genome of the strain contains a combination of at least (6) different cry genes and at least (3) different Vip genes that has not been described for other Bt strains and that can be used to identify it.

Claims

1. A strain of Bacillus thuringiensis which is characterized by: being the strain SVBS-1801 deposited in the Colección Española de Cultivos Tipo (CECT) with the deposit reference number CECT 9753.

2. A method for preparing a composition comprising a mixture of crystals and spores of the SVBS-1801 strain of claim 1, which comprises the steps of: a) growing SBVS-1801 bacteria until more than 50% of the bacterial cells have undergone sporulation, have lysed and released their crystals and spores to the culture medium; b) purifying the crystals and spores by provoking their sedimentation from the culture medium where they are in suspension, preferably by centrifugation, and collecting the precipitate; c) optionally, washing the precipitate with a protease inhibiting solution and provoking again the sedimentation of the crystals and spores; d) storing the purified crystals and spores either: a. at room temperature, after having lyophilized the precipitate obtained in step b) or c), or b. at a temperature of the interval of −18° C. to −20° C. or lower, after having resuspended the precipitate obtained in b) or c) in water or in an aqueous solution.

3. A method for obtaining purified crystals of the B. thuringiensis strain of claim 1, which comprises the steps of: i) washing a mixture of crystals and spores of the strain of claim 1 with NaCl 1M and centrifuging it at 9000 g for 10 min., ii) collecting the pellet and resuspending it in PBS, iii) adding hexane to the suspension obtained in step ii) and vortexing it; iv) centrifuging the suspension of iii) at 6000 g, 4° C., 10 min, v) repeating steps ii) to iv) at least three times, vi) colleting the pellet of crystals obtained in v) and washing it three times in cold destilled water.

4. A composition which comprises: a) vegetative cells, b) bacterial cells containing spores, c) spores, d) crystals, e) a mixture of spores, crystals and crystal proteins, f) Cry proteins not included in a crystal, g) at least a Vip protein, or combinations thereof, of the Bacillus thuringiensis strain of claim 1, wherein, when no member of the group defined in a) to e) is present a. the composition comprises at least a Cry protein not included in a crystal and at least the protein of SEQ ID NO:8 is present in the composition, and/or b. all the three Vip proteins of the group of proteins of SEQ ID NO:14, SEQ ID NO:16 and SEQ ID NO: 18 are present in the composition.

5. The composition according to claim 4, wherein the composition additionally comprises a portion of the supernatant obtained in step b) of the method of claim 2.

6. The composition according to claim 4 or 5, which comprises at least either a) a mixture of spores and crystals, b) a mixture of spores, crystals and a portion of the supernatant obtained in step b) of the method of claim 2, c) crystals, d) crystals and a portion of the supernatant obtained in step b) of the method of claim 2, of the Bacillus thuringiensis strain of claim 1.

7. The composition according to claim 6, which comprises either crystals or a mixture of crystals and a portion of the supernatant obtained in step b) of the method of claim 2, wherein the crystals have been previously purified by the method of claim 3 and the composition is essentially free of spores of the Bacillus thuringiensis strain of claim 1.

8. The composition according to claim 4, which comprises at least a mixture of spores, crystals and crystal proteins of the Bacillus thuringiensis strain of claim 1.

9. The composition according to claim 4, which comprises Cry proteins not included in crystals and wherein the composition comprises at least all the Cry proteins of the group of SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8, not being included in crystals.

10. The composition according to any one of claims 4 to 8, which additionally comprises an inhibitor of the germination of spores.

11. The composition according to any one of claims 4 to 10, which additionally comprises at least an agriculturally acceptable excipient.

12. Use of the B. thuringiensis strain of claim 1 or the composition of any one of claims 4 to 11 as an insecticide or to prepare an insecticide.

13. The use according to claim 12, to control insect pests of the species Spodoptera frugiperda.

14. The use according to any one of claims 12 to 13 to protect plants.

15. A method for identifying the presence of a B. thuringiensis strain of claim 1, which comprises a step where it is determined either a) that the genome of the strain comprises: i) at least a gene or DNA region whose sequence is selected of the group of SEQ ID NO:1 or SEQ ID NO:7, or combinations thereof; and/or ii) at least all the genes or DNA regions of the group of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11, and/or iii) at least all the genes or DNA regions of the group of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17; and/or iv) all the genes or DNA regions of the group of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17; or b) that the strain expresses i) at least a polypeptide whose amino acid sequence is SEQ ID NO:2 or SEQ ID NO:8, or combinations thereof, and/or ii) at least all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12, or iii) at least all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18, iv) all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0065] FIG. 1. Morphology of SVBS-1801: A) vegetative cells (VC); B) bacterial cells containing the fully formed spore and crystal just before cell lysis; and C) spores and crystals already released as a result of the lysis of the bacterial cell.

[0066] FIG. 2. Results of the comparative analysis of the beta-exotoxin production by the positive control strain BT2 (strain Bt HD2) and the sample strain BT4 (SVBS-1801).

[0067] FIG. 3. SDS PAGE of ABTS-351 (Dipel®), ABTS-1857 (Xentari®) and SVBS-1801 purified crystals (Lanes 2, 3 and 4, respectively). A molecular weight marker is included (lane 1).

[0068] FIG. 4. Nucleotide sequence alignment of the SVBS-1801 cry1Ab24-like gene (Sbjct) and its most similar reference gene cry1Ab24 (Query).

[0069] FIG. 5. Nucleotide sequence alignment of the SVBS-1801 cry2Ja1-like gene (Sbjct) and its most similar reference gene cry1Ja1 (Query).

[0070] FIG. 6. Amino acidic sequence of the SVBS-1801 Cry1Ab24-like protein (Sbjct) and its most similar reference protein Cry1Ab24 (Query), where it can be observed that the reference protein Cry1Ab24 has 26 additional amino acids between the position 793 and 794 of the sequence of the SVBS-1801 Cry1Ab24-like protein sequence (SEQ ID NO:2)

[0071] FIG. 7. Amino acidic sequence of the SVBS-1801 Cry1Ja1-like protein (Sbjct) and its most similar reference protein Cry1Ja1 (Query).

[0072] FIG. 8. Mortality percentages for S. frugiperda larvae collected 12, 24, or 36 hours after treatment with the ABTS-1857 and SVBS-1801 strains using 100 mg/L of the spore/crystal mixture.

DETAILED DESCRIPTION OF THE INVENTION

[0073] The present invention is based on the finding, isolation and characterization of strain SVBS-1801 of B. thuringiensis, which has proven insecticidal activity against S. frugiperda larvae. It contains at least 6 cry genes and 3 vip genes, respectively.

[0074] Two of the cry genes found in this strain (those whose coding sequences match SEQ ID NO:1 and SEQ ID NO:7, respectively) can be considered new genes which have not been previously isolated and sequenced, because they are not identical in their coding sequence to any known cry gene, so that the determination of the presence in the genome of any one of said two genes or preferably both of them, can be used to identify a B. thuringiensis bacterium as a bacterium of this novel strain. However, their degree of identity with reference known genes, cry1Ab24 and cry1Ja1, respectively, is high (98% in the first case and 94% in the second one), so that they have not been considered strictly different genes and they have been named cry1Ab24-like and cry1Ja1-like, respectively.

[0075] The novel strain SVBS-1801 possesses a set of 6 cry genes and 3 vip genes different from those of other known varieties. Each of the mentioned sets of genes can be considered unique and characteristic of this novel strain, not having been described in other B. thuringiensis strains.

[0076] Therefore, the determination of the simultaneous presence of the set of 6 cry genes or of the 3 vip genes or, preferably, of the 9 genes, is useful to identify the strain and distinguish it from other Bt strains. Any method for identifying a B. thuringiensis strain which comprises the determination of the presence of any (or both of them) of the genes of SEQ ID NO:1 and SEQ ID NO:7, and/or the simultaneous presence of the set of 6 cry genes of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11 and/or the simultaneous presence of the set of 3 vip genes of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17 or the simultaneous presence of the two set of genes, concluding that the strain is the B. thuringiensis strain SVB S-1801 if the mentioned genes for each alternative are present, will be considered comprised within the scope of the present invention and an aspect of it. The detection of the expression of at least one of the proteins encoded by SEQ ID NO:1 and SEQ ID NO:7, that is, the proteins of SEQ ID NO:2 and SEQ ID NO:8, respectively, can be also used to identify the SVBS-1801 strain. Analogously, the strain can be identified by determining the expression of the polypeptides encoded by the sets of genes mentioned above, that is, determining, and confirming, the expression of at least all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12 (the set of Cry proteins encoded, respectively, by the set of genes of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11, whose simultaneous presence in a Bt genome is characteristic of the Bt strain of the present invention), and/or the expression of at least all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18 (the set of Vip proteins encoded, respectively, by the set of genes of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17 whose simultaneous presence in a Bt genome is characteristic of the Bt strain of the present invention) or all the polypeptides of the group of polypeptides whose amino acid sequence is SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16 or SEQ ID NO:18, can be used to identify the presence of the Bt strain SVBS-1801 of the present invention.

[0077] As it is used in the present application, “identifying the presence” can be understood as determining the presence of the Bt strain SVBS-1801 in a sample or identifying that a certain strain is the Bt strain SVB S-1801 of the present invention. As genes cry1Ab24-like and cry1-Ja1-like are novel and different even from the most similar known genes (cry1Ab24 and cry1Ja1) and their simultaneous presence is the genome of a Bt strain has not been described previously, they can be also used to define the novel strain of the present invention particularly cry1Ja1-like or the protein encoded by it, because it exhibits activity against S. frugiperda. As commented above, neither the simultaneous presence of the set of cry genes of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11 nor the simultaneous presence of the set of vip genes of SEQ ID NO:13, SEQ ID NO:15 or SEQ ID NO:17 have been previously reported for a Bt strain, so that any of such two set of genes, or the simultaneous presence in the genome of all of them, can be used, too, to define the Bt strain of the present invention by means of features that are characteristic of said strain and that were not obvious or expected to find, particularly in a strain not created in a laboratory but isolated from an environmental source. This comment of the utility for defining the strain by means of the specific combinations of cry and vip genes that can be found in about can be extended to the proteins encoded by the mentioned genes.

[0078] Strain SVBS-1801 which was deposited on Colección Española de Cultivos Tipo (CECT) on 14 Nov. 2018, and received the accession number: CECT 9753, is one aspect of the present invention.

[0079] Regarding the proteins encoded by the cry and/or vip genes found in the SVBS-1801 Bt strain, all identified Cry proteins may be present in the crystal, while Vip proteins should be found in the supernatant of the growth medium after being secreted during the growth phase.

[0080] It is noteworthy that the toxicity spectrum of this strain includes S. frugiperda, which is not satisfactorily controlled by the currently biological available products in the market. No previous knowledge indicated that a strain showing the combination of genes mentioned above could have activity against S. frugiperda, and, specially, there was no previous knowledge indicating that a strain with such particular combination of genes could show higher activity against Spodoptera frugiperda than the strains used to prepare the commercial insecticides that are currently used against this pest, as can be shown in the Examples below. And this is particularly remarkable since the finding of Bt strains with high activity against a specific species, based on genetic and molecular characteristics, is a difficult and unobvious task. As discussed above, such difficulties arise not only from the fact that Cry proteins with high homology might show different activities and specificities against pests, but also, and very especially, because it is unpredictable which combinatorial effects might occur among the different toxins produced by a Bt strain, its type (synergistic or antagonistic), and the degree of influence that the combinatorial effects might have on the insecticidal activity of a Bt strain and its fermentation products. In fact, the present application discloses synergistic effects among three of the Cry proteins produced by the SVBS-1801, given rise to an increase of activity with regard to the expected activity resulting from the simple combination of the activity of each one of said proteins, which is a combinatorial effect that was totally unexpected.

[0081] Thus, the present invention provides a novel Bt strain, SVBS-1801, isolated from an environmental source and that lacks expression of β-exotoxin, that can be used in the control of Spodoptera frugiperda pests. Also encompassed by the invention are methods for preparing compositions comprising mixture of crystals and spores of SVBS-1801 (the kind of compositions that are usually used to prepare commercial insecticides), methods for preparing purified crystals of the strain, compositions comprising different components produced by the strain or resulting from its growing: mixtures of crystals and spores where other components might be also present such as Cry proteins not included in parasporal crystals, vegetative bacteria or Vip proteins, composition with Cry proteins not included in crystals, purified crystals or even composition with purified crystals or with a mixture of crystals and spores where a portion of the supernatant obtained when the liquid culture medium of growing the strain is centrifuged to separate the crystals and spores from the liquid where the bacteria have been growing. The use of the strain, and the compositions comprising it or comprising elements produced by the strain or resulting from its growing in a liquid fermentation medium, as insecticides or for preparing insecticides, particularly against S. frugiperda, are also encompassed by the scope of the present invention.

[0082] This invention also covers the new genes of SEQ ID NO:1 and SEQ ID NO:7, the proteins encoded by SEQ ID NO:1 and SEQ ID NO:7 (namely the proteins of SEQ ID NO:2 and SEQ ID NO:8), and proteins comprising a polypeptide with at least a 99% of identity with SEQ ID NO:2 or SEQ ID NO:8 and with insecticidal properties. Also covered by the invention are all mutant strains that may derive from SVBS-1801, particularly the recombinant bacterial strains obtained with the mentioned genes (that can be obtained, for instance, following the procedure described in Example 4) or, even, recombinant cells of yeasts, fungi or even plant cells, as well as vectors that allow the expression of the mentioned proteins or the insertion of the genes of SEQ ID NO:1 or SEQ ID NO:7 in its genome, such as plasmids or recombinant viruses In the case of plant cells, the insertion not only of the gene of SEQ ID NO:7, but also of the gene of SEQ ID NO:3 and SEQ ID NO:5, or the introduction of expression vectors of all the three genes, might be of interests, since the proteins expressed by said three genes have shown activity against S. frugiperda when tested separately, but they have also shown synergistic effects when tested in combination.

[0083] B. thuringiensis strain SVBS-1801 presents the following characteristics:

[0084] Growth: B. thuringiensis SVBS-1801 grows preferably at 28-30° C. in salt-rich media such as the CCY medium described and used in Example 1 of the present invention. In such conditions, spores germinate and produce a bipyramidal crystal that can be observed under an optical microscope (FIG. 1). When grown in solid media (CCY or Luria-Bertani (LB) broth, supplemented with agar), the morphology of the colonies is very similar to that of other Bt strains, rounded with an irregular edge and a waxy appearance. SVBS-1801 can be grown at an industrial scale when using in the appropriate media: salt-rich media such as the CCY medium and temperature conditions, which may vary between 15-45° C., although the optimal range goes from 28 to 30° C. A continuous agitation (220 rpm, for instance) is also required.

[0085] Absence of exotoxin. As explained above, some Bt strains may produce a secreted exotoxin, β-exotoxin, which can impair the RNA polymerase and cause cell mortality to a wide variety of species and preventing the use of the strain, or product based on it, as an insecticide. As shown in Example 2, SVBS-1801 does not produce β-exotoxin during the fermentation process. For this reason, it is considered to have a wide and unspecific range of action.

[0086] Bt toxins/crystal proteins: The Cry proteins synthetized by the strain SVBS-1801 of the present invention, aggregate and crystalize during the sporulation phase, giving rise to parasporal crystals, which are named simply “crystals” in the present application. Their pattern of migration in SDS-PAGE gels can be described as two bands in close proximity to each other with an approximate weight of 120-135 kDa (Cry1Ab, Cry1Da3, Cry1Ea7 and Cry1Ja1) (FIG. 3). Crystal proteins from the commercial products based on the strain ABTS-351 (Bt strain of serovar kurstaki), Dipel®, (Cry1Aa, Cry1Ab, Cry1Ac y Cry2Aa) and on the ABTS-1857strain (Bt serovar aizawai), XenTari® (Cry1Aa, Cry1Ab, Cry1Ca, and Cry1Da) migrate similarly, with bands of a comparable weight to those of strain SVBS-1801 (130-135); however, the total pool of proteins produce unique migration patterns for each strain. It is known that Dipel® additionally generates a band of about 70-75 kDa that corresponds to protein Cry2Aa.

[0087] Insecticidal capacity. As mentioned above, it is noteworthy that SVBS-1801 crystal proteins are 5.7 and 1235.4 fold more effective against S. frugiperda than their XenTari® and Dipel® counterparts, respectively, as indicated in the Examples of the present application. Thus, products based on SVBS-1801 strain (that is, compositions comprising vegetative cells, bacterial cells containing spores, spores, crystals, Cry proteins or Vip proteins, or combinations thereof), of SBVS-1801, can be used as an insecticide or for the preparation of insecticides. It is particularly preferred that the active ingredient used to prepare such insecticide composition is a combination of spores and crystal proteins obtained after subjecting to a precipitation process (preferably, by centrifugation) the content of a culture (understanding as such the culture medium and the grown bacterial cells, remains of lysed cells and bacterial products such as spore, crystals, bacterial proteins not forming part of crystals and other bacteria produced compounds) where SBVS-1801 bacteria have been grown until they have undergone sporulation, lysis and release of their crystals and spores, as in Example 1: the equivalent to the active ingredients used for the preparation of Bt based commercial insecticide products such as Dipel® or Xetari®.

[0088] Such active ingredient (AI) (strain SVBS-1801) and the mixture of crystals and spores usually included in its formulation, can be acquired as explained in Example 1 or by any analogous method. It is as aspect of the present invention a method which comprises the steps of: [0089] a) growing SBVS-1801 bacteria until more than 50% of the bacterial cells have undergone sporulation, have lysed and released their crystals and spores to the culture medium; [0090] b) purifying the crystals and spores by precipitating them from the culture medium in which they are in suspension, preferably by centrifugation, and collecting the precipitate; [0091] c) optionally, washing the precipitate with a protease inhibiting solution and provoking again the sedimentation of the crystals and spores; [0092] d) storing the purified crystals and spores either: [0093] a. at room temperature, after having lyophilized the precipitate obtained in step b) or c), or [0094] b. at a temperature of the interval of −18° C. to −20° C. or lower, after having resuspended the precipitate obtained in b) or c) in water or in an aqueous solution.

[0095] Such AI contains a mixture of crystals and spores that can be reformulated as a composition in the form of a concentrated liquid suspension or as a wettable powder, which composition can also contain one or more excipients or additives, particularly those commonly use in the agricultural field. Any of such reformulated forms could be applied to the fields and can be used as an insecticide, preferably to protect plants. As commented above, it can be used to control pests, for example S. frugiperda.

[0096] But it is remarkable that one of the advantages of the strain SVBS-1801 is that the present inventors have found that different compositions with different elements produced by the strain SVBS-1801 of the present invention also have activity against S. frugiperda, which observed activity, in some of the treatments, is even higher than the activity of the mixture of crystals and spores obtained by the method of the invention mentioned above. Adding a portion of the supernatant obtained by the same method to the mixture of crystals and spores gives rise to a significant increase in the activity, as it is shown by the LC.sub.50 value (see Table 5). The assays carried out with purified crystals, free of spores, also show an increase in activity with regard to the mixture of crystals and spores, which is even higher (lower values of LC.sub.50) when the crystals are mixed with the same supernatant. These results facilitate the use of different compositions for the preparation of AIs, each one with different components produced or derived from the strain SVBS-1801, namely: a) a mixture of spores and crystals; b) a mixture of spores, crystals and a portion of the supernatant obtained by performing steps a) and b) the method of preparing a mixture of spores and crystals of strain SBVS-1801 which is an aspect of the present invention; c) crystals; d) crystals and a portion of the supernatant obtained by performing steps a) and b) the method of preparing a mixture of spores and crystals of strain SBVS-1801 which is an aspect of the present invention.

[0097] The purified crystals can be prepared by the method used in Example 8, which is also an aspect of the invention, but also by any other method known by those skilled in the art, such as the ultracentrifugation on a sucrose gradient (Thomas and Ellar, 1983), which will usually be a discontinuous sucrose gradient (79-67%), where the crystal are trapped in the interphase and the spores can be collected from the pellet. A crystal preparation, or a composition comprising SBVS-1801 crystals, will be considered free, or essentially free, of spores if no spore is observed by confocal microscopy of samples of the preparation or composition, as described in Example 8 of the present application, or when the presence of spores is checked by an analogous method.

[0098] When spores are not desired in the composition, the purification of the crystals can be replaced by the addition of a germicide. The germicide can also be added to compositions with purified crystals, in order to guarantee the absence of spores by eliminating any possible spore that might remain after the crystal purification. The absence of spores can be checked by inoculating dilutions of the suspension of purified crystals in nutritive agar plates and verifying that no colony grows, and, consequently, the crystals are completely free of spores and its purity is maximal. If added, the germicide will be preferably selected to be compatible with the ecological properties of the strain and compositions of the present invention.

[0099] The results obtained in Example 8, where both the mixture of spores and crystals and the purified crystals show activity against S. frugiperda, indicates that it is possible to envision the preparation of mixtures of spores and crystals with different proportions of said elements (such as, for example, 50:50 or 80:20 crystals:spores, or any other), being possible to use all of them for the preparation of the active ingredient of an insecticide. Thus, for instance, one must consider comprised within the present invention those compositions with contains spores and crystals, where the crystals have been obtained by a method that give rise to crystals are not completely purified but they are only, for instance, 80% purified (or any other percentage such as 85%, 90% or 95% purified), so that the preparation will be, indeed, a mixture of crystals and spores also comprised within the scope of the present invention.

[0100] Also in Example 8, but in section 8.3., assays about the toxicity of the individual Cry proteins synthesized by the strain of the present invention are shown. In accordance with the results obtained (see Tables 6 and 7), the insecticidal activity of the parasporal crystals of the strain SVBS-1801 could be attributed to the Cry proteins Cry1Da3, Cry1Ea7 and Cry1Ja1-like, which are toxic when tested individually against S. frugiperda larvae. The activity of the protein Cry1Ja1-like is remarkable, because it is encoded by one the genes disclosed in the present application, cry1Ja1-like (SEQ ID NO:7), which shows certain differences with the already known gene cry1Ja1, as discussed above. Particularly noteworthy is the fact that the assays carried out with a mixture of the three proteins show an increase of activity with regard to the same concentration of any of the three proteins, indicating a combinatorial synergistic effect in the mixture of the three proteins, that has been confirmed in the same section of Example 8. The identified synergistic effect was not expected from the teachings of previously published documents and supports that it was not expectable that a strain with the combination of genes of SVBS-1801 could have high activity against S. frugiperda, particularly against larvae, which activity is higher than that of the most potent commercial insecticide currently on use against this strain, Xentari® (see Examples 9 to 11) and to that of the most potent strain described by Capalbo et al. (2001), to the extent that the lack of explanation about the methodology used to measure the LC.sub.50 in the assays reported in that article allows a comparison.

[0101] The results found in the assays with Cry proteins make also possible to consider compositions comprising a mixture of proteins Cry1Da3, Cry1Ea7 and Cry1Ja1-like (SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO.8, respectively) as possible embodiments of the compositions of the present invention, particularly if they are in equimolar proportions. Such compositions can also be of use as insecticides or for the preparation of insecticides against S. frugiperda.

[0102] Insecticidal genes. As specified in Tables 2 and 3, the genome (chromosome+plasmids) of SVBS-1801 contains at least 6 different cry genes and 3 different vip genes, respectively. Two of the cry genes (cry1Ab24-like and cry1Ja1-like) are not completely identical to the most similar reference genes whose coding sequence is publicly available, cry1Ab24 (GenBank accession number HQ439778) and cry1Ja1 (GenBank accession number L32019). Therefore, the determination of the presence of at least one of said genes, which are different from other known Bt genes, might be enough to identify the strain SVBS-1801. To that aim, it is noteworthy that gene cry1Ab24-like presents a coding sequence (SEQ ID NO:1) 78 nucleotides shorter than the coding sequence of cry1Ab24 (see FIG. 4), which results in the protein encoded by cry1Ab24 being 26 amino acids longer between positions 793 and 794 of the polypeptide encoded by SEQ ID NO:1 (see the alignment of FIG. 6). Such difference in size and sequence, in addition to the presence of T instead of C in the position 906 of SEQ ID NO:1, can be useful to differentiate cry1Ab24-like from cry1Ab24 (GenBank accession number HQ439778). Regarding cry1Ja1-like, as indicated in FIGS. 5 and 7, its coding sequence is identical in length to the coding sequence of cry1Ja1 (GenBank accession number HQ439784) but there are two different nucleotides between both sequences. The reference gene cry1Ja1 presents a T instead of a C in position 987 of SEQ ID NO:7 and a G instead of an A in position 2345 of SEQ ID NO:7, respectively. These are variations that can be used to differentiate the sequences belonging to strain SVBS-1801.

[0103] The identification of the SVBS-1801 strain can be done by determining the presence of the set of six cry genes found in SVBS-1801 by the present inventors, as indicated in Table 2 (cry1Ab24, cry1Da3, cry1Ea7, cry1Ja1, cry1Nb1, cry2Ad1, or by the presence of the set of three vip genes found in SVBS-1801 by the present inventors, as indicated in Table 3 (vip1Ca1, vip2Ac1, vip3Af3) or, more preferably, by the simultaneous presence of at least the nine insecticidal genes, the set of six cry genes and the set of three vip genes. The identification of the presence of the selected genes can be done as in Example 3, with a complete DNA sequencing, contig assembling and gene prediction of the assembled contigs, or by any other method; analogously to the method used in Example 3, or by amplifying the gene fragments by PCR, as in Example 4, using for instance the same pairs of primers. The presence of a gene will require at least 95% of identity with the sequence of the gene in the database btnomenclature (http://www.btnomenclature.info, which database contains Bacillus thuringiensis genes that are also present in Genbank and which can be accessed with the same accession number), as it might correspond but it will be preferred that, when gene cry1Ab24 or the gene cry1Ja1 is one of the genes used to identify a strain as the SVBS-1801 strain, the presence of gene cry1Ab24 or the gene cry1Ja is considered positive when the sequence of the corresponding DNA fragment is that one of SEQ ID NO:1 or that of SEQ ID NO:7, respectively, that is, the variants of said genes found in the strain SVBS-1801.

[0104] Genes and their uses. Strain SVBS-1801 may be used as a source of genes with a wide variety of applications in other fields like medicine, veterinary, biotechnology, etc. and they may be transferred, alongside their biological properties, to other organisms for different purposes. Thus, the genes whose coding sequences are those of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17, are products of interest by themselves since they encode insecticidal proteins. Said genes (or the DNA fragments or regions where they are comprised) can be used, for instance, to obtain transgenic plants with insect resistance (analogously to the plants described in documents such as international patent application WO1995/024493 or United States application published as US20080016596A1) or nematode resistance (analogously to the plants described in documents such as international patent application WO2010/027793), for instance by using the techniques described in such documents, which are well known for those skilled in the art. The same DNA fragments or regions, can be used to obtain, for instance, non-human transgenic animals or recombinant cells (animal, plant, fungal or bacterial cells), provided that they are part of a construct where they are operatively linked to the appropriate control elements (promoters, enhancers . . . ), depending on the conditions when they are desired to be expressed or, in the case of transgenic plants or animals, also depending on the tissues where their expression is desired. Such control elements are well known by those skilled in the art. The construct can be integrated in the genome or, particularly for the case of bacterial recombinant cells, can be part of an expression vector such as a plasmid, that can be introduced in the cell by methods well known by those skilled in the art. Such transformed cells or higher organisms can be useful to give rise to plants resistant to pest such as nematodes or insects (such as, for instance, insects of the Spodoptera genus, like S. frugiperda) or can be used for any other purposes (medical, veterinary, research in general . . . ).

[0105] Thus, it must be considered comprised within the scope of the invention any nucleic acid molecule comprising a fragment whose nucleotide sequence is: a) the sequence of any of the new genes of the present invention (SEQ ID NO:1 and SEQ ID NO:7), b) any nucleotide sequence which encodes a polypeptide comprising the amino acid sequence of any of the proteins encoded for the mentioned genes (the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:8, which are the proteins of the present invention), as well as the nucleotide sequences which also encodes proteins comprising a polypeptide fragment sequence of SEQ ID NO:2 or SEQ ID NO:8, but which are different from SEQ ID NO:1 and SEQ ID NO:7, due to the degenerative nature of the genetic code) or proteins comprising a polypeptide fragment which is similar as those of the present invention in sequence and activity but that they cannot be classified as different proteins, that is: c) a nucleotide sequence which encodes a polypeptide having a sequence fragment of at least 98.5% (or at least 99%, 99.5%, 99.90%, 99.95% or 99.99%) of identity with the amino acid sequence of SEQ ID NO:2 or at least 99.85% (or at least 99.90%, 99.95% or 99.99%) of identity with the amino acid sequence of SEQ ID NO:8 and with pesticidal activity (insecticidal, nematocide, or both of them). The pesticidal activity can be shown by the polypeptide as such or by a cleavage form thereof, as happens usually with Cry proteins, whose insect toxic activity appears after the protein is cleaved in two fragments in the insect gut.

[0106] Accordingly, the constructs containing any of such nucleic acid molecules of the invention and, particularly, the expression vectors (plasmids or recombinant viruses, for instance) where the nucleic acid molecules of the invention are operatively linked to a promoter and, optionally one or more control sequences, selected depending on the conditions where the protein is desired to be expressed and/or depending on the desired level of expression, are all also contained in the scope of the present invention.

[0107] Also part of the scope of the invention is any cell (bacterial, fungal, yeast, or plant cell) which comprises a nucleic acid molecule of the invention as a heterologous DNA fragment, or which comprises an expression vector thereof. The nucleic acid fragment can be integrated in the genome (or, in the case of bacteria, in the bacterial chromosome) or can be part of other nucleic acid elements such as plasmids or non-integrative viruses. The bacterial cell can even come from another B. thuringiensis strain, for instance one that does not naturally contain one or more of the genes of: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 or SEQ ID NO:17 and whose insecticidal or nematocidal activity can be increased or modified by the expression of one or more of the proteins matching sequences SEQ ID NO.2 and SEQ ID NO:8. This may be achieved by transforming the strain with a cassette comprising a DNA fragment of SEQ ID NO:1 or SEQ ID NO:7 (or any other nucleotide sequence encoding the polypeptide of sequence SEQ ID NO:2 or SEQ ID NO:8) operatively linked to a promoter that allows the expression of the polypeptide in the strain, either constitutively or under selected conditions. Additionally, those recombinant B. thuringiensis cells which, after the modification of its genome (chromosome and plasmids included), contain at least one of the set of genes whose coding regions match sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11 or by SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17, or both sets of genes, because it will have become a Bt strain with the characterizing genome of the strain SVBS-1801, are included in the present invention.

[0108] Also consequently, any plant which comprises a DNA molecule of the invention will be comprised within the scope of the present invention, particularly when the DNA molecule or fragment is part of a construct where it is operatively linked to one or more control elements (promoters, enhancers, termination sequences . . . ) which allow or facilitate the expression of the polypeptide encoded by the DNA molecule in one or more tissues of the plant or animal, constitutively or under certain conditions, including different times in the development process of the plant or animal. For transgenic plants, (as reviewed, for instance, by Shah et al., 2015) constitutive promoter such as the cauliflower mosaic (CaMV) 35S are commonly used, but it could be also interesting to be able to restrict the expression of the desired transgenic gene by the use of inducible promoters such as the wound inducible promoter of tomato HMGR2 gene, the PR-1a promoter (induced by pathogen infection and chemical elicitors such as benzothiadiazole) or the maize In2-2 (inducible gene 2-2) promoter (which is induced by benzene sulfonamide safeners which act as herbicide tolerance increasing agrochemicals of plants). Other inducible elements of interest can be the cis-acting regulatory sequences that spatially regulate the expression of genes at different parts, or the two upstream activating sequences encoded by the promoter of the phaseolin gene, UAS1 (-295 to -109) and UAS2 (-468 to -391). Besides, targeted expression to specific tissues is becoming more important for the future development of value-added crops, so that promoters like the one of the ACC oxidase gene which, ranging from 21966 to 21159 bp from the start of transcription, is able to drive tipening-specific expression of a gene in fruits such as the tomato fruit, as it has been also reviewed by Shah et al., 2015.Other different promoters and control elements can be found in the mentioned revision and in other documents available for those skilled in the art.

[0109] The invention will be now explained with further detail with the examples and drawings included below.

EXAMPLES

[0110] The following section provides examples that illustrate the procedures in which the invention may be applied to facilitate the industrial exploitation of SVBS-1801.

Example 1.—Isolation and Growing of Bt Strain SVBS-1801

1.1. Isolation of the Strain SVBS-1801

[0111] The SVBS-1801 strain was obtained from a sample of agricultural soil from the outskirts of the city of Badajoz, used in the construction of the gardens of the urbanization “Residencial San Gabriel” of this city. Said soil samples were collected in December 2016 and kept under refrigeration conditions (4° C.) until the moment of processing (January 2017). To carry out the isolation and identification of the SVBS strain, samples were collected from the soil, after removing the first layer, mixed with distilled water and heated at 70° C. for 15 min. A volume (15 μl) of a ten-fold dilution was plated onto CCY medium and incubated at 28° C. for 72 h. Positive Bt colonies were checked by phase contrast microscopy (Iriarte et al., 1998).

1.2. Growth in a Culture Medium that Promotes Sporulation

[0112] A sample of SVBS-1801 is grown in 1 L of CCY medium (Stewart et al., 1981). CCY is a minimum medium that promotes sporulation, which ultimately leads to the formation of crystals and spores (FIG. 1). It is prepared by mixing buffer ingredients (Solution 1) and carbon source ingredients (Solution 2) in the appropriate proportions. Once the mix is complete, the medium is sterilized inside an autoclave and supplemented with 1 ml of a previously filtered salt solution (Solution 3).

TABLE-US-00001 TABLE 1 CCY medium (Stewart et al., 1981) Solution 1. Buffer solution, pH 7 (500 ml) KH.sub.2PO.sub.4 0.026M K.sub.2HPO.sub.4 0.052M Solution 2. Carbon source (10 ml) L-glutamine 0.2 g Casein hydrolysate 10 g Bacto casitone 10 g Yeast extract 4 g Glycerin 6 ml Deionized H.sub.2O Up to 100 ml Solution 3. Salts solution (1 ml) ZnCl.sub.2 0.05M MgCl.sub.2•6H.sub.2O 0.5M MnCl.sub.2•6H.sub.2O 0.01M CaCl.sub.2•2H.sub.2O 0.2M FeCl.sub.2•6H.sub.2O 0.05M HCl 1%

[0113] Bacterial growth is initiated by transferring 100 μl from a SVBS-1801 over night (ON) preinoculum to the CCY medium (1:1). Bacteria are grown at 30° C. and 220 rpm for 48-72 h. The fermentation process concludes once 95% of the SVBS-1801 cells, which have undergone a sporulation process, lysate and release their crystal and spore. To verify that such stage has been achieved, 1 ml samples of the culture should be analyzed under an optical microscope.

[0114] To purify the crystals and spores that have been produced, the contents of the culture are centrifuged, and the precipitate is then washed with a 10% solution of NaCl 1M/EDTA 10 mM. Such solution is utilized to prevent proteases from degrading the protein crystals. Subsequently, the culture is again centrifuged, and the pellet is lyophilized and stored at room temperature until formulated or resuspended in KCl 10 mM (10 ml initial culture) and stored at −20° C.

Example 2.—Characterization of strain SVBS-1801: Procedure to Determine if Strain SVBS-1801 Produces β-exotoxin

[0115] To determine if a particular Bt strain is β-exotoxin positive, the supernatant of the growth medium should be analyzed. For this purpose, the procedure used by Hernández et al., 2003, was used. Thus, a colony of Bt SVBS-1801 and HD-2 strains (used as a positive control) are grown in 10 ml of CCY at 30° C. and 220 rpm for 48 h. Next, cultures are centrifuged at 9000×g for 10 min and their supernatants transferred to new tubes and sterilized in an autoclave at 120° C. and 1 atm for 20 min.

[0116] To detect the presence of β-exotoxin an HPLC is performed. KH.sub.2PO.sub.4 (50 mM, pH 3), at a flow rate of 2 ml min, constitutes the mobile phase and is filtered alongside the sterilized supernatant through a nylon membrane of 0.45 μm. 20 μl of supernatant are analyzed in a μ-Bondapak C18 column at 25-30° C. and 260 nm. If the β-exotoxin is present, two clear peaks indicating its phosphorylated and dephosphorylated form should appear. In the present case, as shown in FIG. 2, such peaks were not detected.

Example 3.—Characterization of Strain SVBS-1801: DNA Extraction, Sequence, and Genomic Sequence Processing

3.1. DNA Extraction, Sequence, and Genomic Sequence Processing

[0117] Total DNA of SVBS-1801 was isolated using the components and following the protocol for DNA isolation from Gram-positive bacteria supplied in the Wizard® Genomic DNA Purification Kit (Promega, Madison, Wis., USA). The extracted DNA samples were used to prepare DNA libraries and subsequently were sequenced with Illumina NextSeq500 Sequencer in the Genomics Research Hub laboratory (Cardiff School of Biosciences, UK).

[0118] The analysis of the generated raw sequence data was carried out using CLC Genomics Workbench 10.1.1. Raw sequence data were quality filtered by removing low quality or ambiguous reads. Reads shorter than 50 bp were discarded. Reads were de novo assembled using a stringent criterion of an overlap of at least 95 bp of the read and 95% identity. Gene prediction on the assembled contigs was done using GeneMark.hmm prokaryotic 3.25. The predicted protein sequences obtained were compared using BLASTP to a database built from the Bt toxin list http://www.btnomenclature.info (Crickmore et al., 2018).

[0119] This bioinformatic analysis allowed the present inventors to identify the complete gene sequence of insecticidal genes. Regardless, some cry and vip gene fragments were identified, as described below.

3.2. Insecticidal Genes Identified

[0120] Table 2 includes a full list of all cry gene fragments (coding sequences) identified in SVBS-1801, indicating their degree of identity (% id.) with closely related insecticidal genes previously described in: http://www.btnomenclature.info. The percentage of coverage of the identified sequences included in the comparison (% cov.), as well as the number of nucleotides (Ntd.) of the sequences identified in SVBS-1801 and the sequences present in the database are also indicated.

TABLE-US-00002 TABLE 2 SVBS-1801 cry gene content SVBS-1801 Database* cry gene SEQ ID NO: Ntd % id. % cov. cry gene Acc. Num. Ntd cry1Ab24-like 1 3456 98 100 cry1Ab24 HQ439778 3531 cry1Da3 3 3492 100 100 cry1Da3 HQ439784 3492 cry1Ea7 5 3516 100 100 cry1Ea7 AY894137 3516 cry1Ja1-like 7 3504 94 100 cry1Ja1 L32019 350 cry1Nb1 9 2016 100 100 cry1Nb1 KC156678 2031 cry2Ad1 11 1902 100 100 Cry2Ad1 AF200816 1902 *Database: http://www.btnomenclature.info

[0121] Similarly, Table 3 contains a complete list of all the vip or sip gene fragments identified in the SVBS-1801 strain, indicating their degree of identity with closely related insecticidal genes previously described in: http://www.btnomenclature.info.

TABLE-US-00003 TABLE 3 SVBS-1801 vip gene content SVBS-1801 Database* cry gene SEQ ID NO: Ntd % id. % cov. cry gene Acc. Num. Ntd vip1Ca1 13 2327 100 100 vip1Ca1 AY245547 2327 vip2Ac1 15 1388 100 100 vip2Ac1 AY245547 1388 vip3Af3 17 2366 100 100 vip3Af3 HM117634 2367 *Database: http://www.btnomenclature.info

3.3. Molecular Characteristics of SVBS-1801 Insecticidal Genes

[0122] Nucleotide sequences of SVBS-1801 cry genes were analyzed using BLAST (Altschul et al., 1990) and the results showed that they presented their highest degree of identity with the genes cry1Ab24 (HQ439778), cry1Da3 (HQ439784), cry1Ea7 (AY894137), cry1Ja1(L32019), cryNb1 (KC156678), and cry2Ad1 (AF200816) from previously described Bt strains (http://www.btnomenclature.info). Analogously, SVBS-1801 vip gene sequences were found closer to previously characterized vip1Ca1 (AY245547), vip2Ac1 (AY245547), and vip343 (HM117634). As reflected in Tables 2 and 3, the percentage of identity was 100% except for the case of cry1Ab24 and cry1Ja1, but the percentage of identity (near 95%) was high enough not to consider the SVBS-1801 genes cry1Ab24-like and cry1Ja1-like different genes according to the usual rules of nomenclature used for B. thuringiensis genes.

Example 4.—Cloning: PCR Amplification of Insecticidal Cry Genes

[0123] Specific oligonucleotide primer pairs, including restriction sites for cloning, were designed to amplify the Open Reading Frames (ORF) of cry1Ab24, cry1Da3, cry1Ea7, cry1Ja1, cry1Nb1 and cry2Ad1 genes based on the sequencing results of the Bt strain. The sequences of said primer pairs are indicated in Table 4 below, where the information in the second column indicates, for each primer, whether it is a forward (Fwd) or a reverse (Rev) primer and, also, the restriction enzyme intended to be used for cloning. The underlined fragment of each primer corresponds to the enzyme cleavage site.

TABLE-US-00004 TABLE 4 Primer pairs used for the amplification of the identified SVBS-1801 genes Oligonucleotide sequence cry gene  (5′-3′) cry1Ab24- Fwd-SalI SEQ ID GGTCGACGGTATCTTA like NO: 19 ATAAAAGAGATGGAG Rev-PaeI SEQ ID GCATGCTTATTCCTCC NO: 20 ATAAGGAGTAATTCCAC cry1Da3 Fwd-SalI SEQ ID GGTCGACGGACTTTAGT NO: 21 AATTTAATAAAAAAAGGG Rev-PaeI SEQ ID GCATGCTTATTCCTCCA NO: 22 TAAGGAGTAATTCCAC cry1Ea7 Fwd-SalI SEQ ID GTGTCGACCAGTACCAA NO: 23 ATTATAAGAACTTTGG Rev-PaeI SEQ ID GCATGCTTATTCCTCCA NO: 24 TAAGGAGTAATTCCAC cry1Ja1- Fwd-SalI SEQ ID GGTCGACAACCAAAGA like NO: 25 GAAAGGGGTAAC Rev-PaeI SEQ ID GGCATGCGTTACAGA NO: 26 GATTAGACGACTAC cry1Nb1 Fwd-SalI SEQ ID GTCGACCTAAAAATAAT NO: 27 GAATATTGGAGGAAAG Rev-PstI SEQ ID CTGCAGCTACATGTTA NO: 28 CGCTCAATATTGAG cry2Ad1 Fwd-SalI SEQ ID GTGTCGACCCTAATAT NO: 29 TTAAGGAGGAATTTTA TATG Rev-PaeI SEQ ID GCGCATGCCTCAAACT NO: 30 TTAATAAAGTGGTG

[0124] DNA extracted from strain SVBS-1801 was used as template in a 50 μl of reaction mixture containing 10 μl reaction buffer 5×HF, 1 μl of dNTPs mixture 100 mM, 1 μl of each forward and reverse primer 10 μM, 0.5 U Phusion High-fidelity DNA polymerase (NEB) and 100 ng of total DNA. PCR cycling profiles were: 1 initial denaturation cycle at 98° C. for 30 s, 30 amplification cycles of 98° C. for 10 s, 55° C. for 1 min and 72° C. for 3 min and 30 s, followed by a final extension step at 72° C. for 10 min in a C1000 Touch thermal cycler (Bio-Rad). The PCR products were analyzed by electrophoresis on a 1% agarose gel in TAE buffer (40 mM Tris, 20 mM acetic acid and 1 mM EDTA; pH 8) at 100 V for 30 min.

[0125] The PCR products corresponding to the cry1Ab, cry1Da, cry1Ea, cry1Ja, cry1Nb and cry2Ad CDS were purified from the agarose gel with NucleoSpin Gel and PCR clean up kit (Macherey-Nagel Inc., Bethlehem, Pa.) and cloned bluntly into the pJET vector (CloneJET PCR Cloning Kit, Fermentas, Canada) to obtain the pJET-protoxin constructions (pJET-1Ab, pJET-1Da, pJET-1Ea, pJET-1Ja, pJET-1Nb and p-JET-2Ad). Transformation of E. coli XL1-Blue was performed following a standard protocol (Sambrook et al., 1989) for recombinant plasmid production containing each of the cry gene CDS. Putative positive clones were checked by PCR in a 20 μl of reaction mixture containing 2 μl reaction buffer 10×NH4, 1 μl MgCl.sub.2 50 mM, 1 μl of dNTPs mixture 100 mM, 1 μl of each forward and reverse primer 10 μM, and 0.2 μl of BioTaq Polymerse (Bioline). E. coli XL1-Blue cells harbouring the pJET constructions were cultured in 5 ml LB broth supplemented with Ampicillin (100 mg/mL) at 37° C. and 200 rpm overnight. Recombinant plasmids were extracted with NucleoSpin plasmid kit (Macherey-Nagel Inc., Bethlehem, Pa.) according to manufacturer's protocol and verified by sequencing using an intermediate forward primer for each gene and the reverse primer for the pJET vector (StabVida, Caparica, Portugal). The cry gene nucleotide and protein sequences were aligned with those of toxins available in the GenBank database using Geneious R8. FIGS. 4 and 6 show the alignment of the sequences of the cry1Ab24-like and cry1Ab24 genes and that of their corresponding protein sequences, respectively; analogously the alignment of the cry1Ja1-like and cry1Ja1 sequences is shown in FIG. 5, while the alignment of their corresponding protein sequences is reflected in FIG. 7.

[0126] Digestion of the recombinant pJET-protoxin constructions of Example 4 was performed with the corresponding combination of restriction enzymes (Thermo Scientific) and subsequent purification of digestion products, previously resolved in an agarose gel, was performed with NucleoSpin Gel and PCR clean up kit (Macherey-Nagel Inc. Bethlehem, Pa.). The expression pSTAB vector (Park et al., 1998), previously digested with the corresponding restriction enzymes, was used as receptor for the inserts using the Rapid DNA ligation kit (Thermo Scientific) to obtain recombinant plasmids with the pSTAB-protoxin constructions. E. coli XL1-Blue cells were transformed with the ligation products, as described before, and putative positive clones were checked by colony PCR before plasmid extraction. An acrystalliferous Bt strain, BMB171 (Li et al., 2000) was used as receptor in a transformation process performed according to previous authors (Cucarella et al., 2001). Putative positive clones were checked for protein production via colony PCR

Example 5.—Protein Expression

[0127] The BMB171-protoxin constructions of Example 4 were cultured in 50 ml CCY medium supplemented with 20 μg/ml erythromycin in a rotary shaker set at 28° C. and 200 rpm for two-three days, until sporulation and lysis of 95% of the cells was observed. Inclusion bodies were observed by phase contrast microscopy at ×1000 magnification. Spore and crystal mixtures were then centrifuged at 9000 g for 10 min at 4° C. Pellets were washed three times in 1 M NaCl, six times in cold water and finally resupended in 10 mM KCl.

[0128] For protein quantification a volume (100 μl) of each recombinant protein was solubilized in 1000 μl of 50 mM Na.sub.2CO.sub.3 (pH 11.3) and 10 mM dithiothreitol (DTT) solution by gentle agitation during 2 h at 37° C. Non-solubilized crystals were removed by centrifugation at 9000 g for 10 min at 4° C. An aliquot (500 μl) was used for protein quantification by Bradford assay (Bradford, 1976) (Bio-Rad) using bovine serum albumin (BSA) as standard.

Example 6.—Molecular Weight of SVBS-1801 Crystal Proteins

[0129] The molecular weight of crystal proteins is usually determined through SDS-PAGE (Laemmli, 1970). In order to do so, a purification of the crystal proteins must be carried out first. Purification may be achieved through different methodologies, including the gradient method proposed by Thomas and Ellar, 1983. Once the crystal proteins are retrieved, a 10 μl aliquot is mixed with 5 μl of 30× Reducing Agent ( 1/10 of the volume) and 3×SDS Sample Buffer (1 volume) (New England Biolabs) and denaturized at 100° C. for 5 min. The mixture is then loaded into a 10% polyacrylamide gel and run for 1 h at 36 mA. Next, the gel is stained using a solution of 50% (v/v) ethanol, 10% (v/v) acetic acid and 0.1% Coomasie blue R 250.

[0130] As shown in FIG. 3, SVBS-1801 presents two bands of about 130 and 133 kDa, which is the size corresponding to Cry1 proteins. Cry2 proteins, in turn, have a size of 633 kDa. The absence of a band in the area corresponding to such size may indicate that protein Cry2Ad1 might not be expressed in the growing conditions used in Example 1.

Example 7.—Procedure for Obtaining SVBS-1801 Active Ingredient (AI)

[0131] The AI may be obtained by growing strain SVB S-1801 in a medium that promotes sporulation, such as CCY (Stewart et al., 1981), as in section 1.2 of Example 1. When 95% of the spore-forming bacterial cells are naturally lysed, the contents of the medium are centrifugated. The resulting pellets should contain a mixture of spores and crystals that were released to the medium during the lysis of the sporulating cells. Concentration by physical dewatering may be done by using a continuous centrifuge operating at >8.000 g to produce a slurry with a solid content of 12-15%, which slurry is the fermentation product with a 50-fold reduction in volume, where the mixtures of spores and crystals are more concentrated but which also includes a part of the liquid and bacterial products comprised in the supernatant. The supernatant contains Vip3A proteins but not Cry proteins, since the only Cry proteins that are secreted to the medium are the Cry1I; as genes cry1I are absent of the genome of the strain SVBS-1801, the mentioned strain cannot synthesized Cry1I proteins and they are absent of the supernatant.

[0132] The centrifugation to obtain the slurry can be followed by either formulation and spray drying to a powder or by direct formulation into a flowable.

Example 8.—Insecticidal Properties of Different Preparations Obtained from SVBS-1801 Culture or Proteins for Neonate Spodoptera frugiperda Larvae

8.1. Spodoptera frugiperda Diet for SVBS-1801 Active Ingredient Toxicity Assays In Vivo

[0133] The standard diet, widely used for rearing S. frugiperda, is a modified version from the tobacco hornworm diet of Hoffman and Lawson (1964).The diet is prepared as follows: ingredients are added in a beaker and thoroughly mixed before being heat sterilized (121° C., 20 min). Antibiotics (streptomycin, chlortetracycline), a vitamin mixture, ascorbic acid and choline must be supplemented when the mixture has cooled to 50° C. The completed diets can be blended with a kitchen mixer. Finally, the diet is poured into sterile containers of 400 ml (17×10×2.5 cm) and allowed to solidify at room temperature.

8.2. Insecticidal Properties of Different Bacterial Preparations Obtained from the SVBS1801 Whole Culture for Neonate Spodoptera frugiperda Larvae

[0134] To determine the concentration-mortality response, insects were treated with different bacterial preparations obtained from the culture of the Bt strain SVBS-1801 (Table 5). Seven concentrations were prepared and tested for each treatment. The treatments were: [0135] As indicated in Example 7, an aqueous solution containing a spores and crystals (S+C) mixture which usually compose the active ingredient of Bt-based products, so that seven concentrations of such aqueous solution were tested. [0136] Furthermore, preparations in presence of the supernatant were tested for possible interactions between the spores and crystals mixture and the secreted toxins that may be present in the culture medium. [0137] Moreover, as the insecticidal toxicity of a Bt strain is mainly attributed to the delta endotoxins that make up the parasporal crystal, crystals were separated from spores and, after recovering the crystals, treatments containing purified crystals were tested to determine their efficacy in absence of the spores. [0138] Besides, possible interactions between the purified crystals and the supernatant were evaluated [0139] Preparations containing spores, supernatant and mixtures of both, spores and supernatant, were also tested.

Preparation of Treatments

[0140] For all treatments, a total of seven concentrations, ranging from 0.3 to 300 ng/μl of insecticidal protein, were prepared from an aliquot previously quantified in order to determine the toxicity of the Bt strain and different products of the strain itself or resulting from the strain culture.

[0141] Aqueous solutions of mixtures of spores and crystals (S+C). A total of seven concentrations, ranging from 0.3 to 300 ng/μl of insecticidal protein, were prepared from an aliquot previously quantified (Example 5) in order to determine the toxicity of the Bt strain.

[0142] Mixtures of spores and crystals (S+C) with supernatant. The corresponding amount of spore and crystal mixture was centrifuged, and the resulting pellet was resuspended in supernatant. The same serial dilutions described for S+C treatment were tested.

[0143] Separation of parasporal crystals from spores and preparation of treatments with purified crystals. A modified version of the protocol described by Mounsef et al 2014 was applied in order to obtain purified crystals from the samples. A volume (200 μl) of a spore and crystal mixture was washed three times with NaCl 1M and centrifuged at 9000 g for 10 min. Pellets were then resuspended in 900 μl PBS 1× and 100 μl of hexane were added. Tubes were vortexed for 1 min and centrifuged at 6000 g, 4° C. for 10 min. The supernatant was discarded and the resulting pellet was subjected to the same procedure at least three times. Crystals were washed three times in cold distilled water and absence of spores was checked by phase contrast microscopy at ×1000 magnification. Quantification of purified crystals was performed as described at the end of Example 5. Treatments containing the amount of purified crystals that corresponded to the concentrations of insecticidal proteins (0.3 to 300 ng/μl) of the S+C serial dilutions were prepared.

[0144] Purified crystals in supernatant. The possible interaction between the purified crystals and the supernatant were evaluated by resuspending the corresponding amount of parasporal crystals, purified as explained in the previous paragraph, in supernatant.

[0145] Purified suspension of spores. In order to obtain a purified suspension of spores a mixture of spore and crystal mixture was subjected to solubilization by adding a solution containing 50 mM Na.sub.2CO.sub.3 (pH 11.3) and 10 mM dithiothreitol (DTT) and by gentle agitation during 2 h at 37° C. Solubilized crystals in the supernatant were removed by centrifugation at 9000 g for 10 min at 4° C. This process was repeated five times. Absence of crystals was checked by phase contrast microscopy at ×1000 magnification. Purified spores were counted on a Petroff-Hausser chamber.

[0146] Spores in supernatant. The different dilutions of the treatment were prepared from the purified spores obtained according to the previous paragraph by adding supernatant.

Bioassay Performance

[0147] All bioassays, including those set up in section 8.3 below, were performed spraying the surface of the artificial diet with the corresponding bacterial preparation using groups of 28 individualized S. frugiperda newly hatched (<12 h) larvae. Toxicity experiments were replicated at least three times on different days using independent preparations and maintained in a controlled environment chamber at 25+1° C. with a 16-h light/8-h dark cycle for 5 days and were checked for mortality. Concentration-mortality data were pooled and subjected to Probit regression analysis (Finney, 1971) in the POLO-PC program (Le Ora Software, 1987). Mean lethal concentration (LC.sub.50) values were considered to differ significantly if their 95% fiducial limits did not overlap.

[0148] The results of the concentration-mortality responses obtained for different preparations containing the spores and crystals mixture and the purified crystals, both in presence and absence of the effect provided by the supernatant are shown in Table 5.

TABLE-US-00005 TABLE 5 Relative potency of the insecticidal activity of different bacterial preparations obtained from the culture of the Bt strain SVBS-1801, for newly hatched larvae of S. frugiperda. LC.sub.50 χ.sup.2 Relative 95% F. L. Bt Treatment Slope ± SE Intercept (ng/μl) (df) Potency Lower Upper S + C Mixture 1.56 ± 0.13 3.67 7.16 7.40 1 — — (3) S + C Mixture + 1.61 ± 0.15 4.23 2.99 6.21 2.39 1.72 3.33 Supernatant (3) Purified Crystals 1.48 ± 0.15 4.28 3.05 4.31 2.34 1.64 3.34 (3) Purified Crystals + 1.02 ± 0.22 4.48 0.25 1.56 28.19 7.27 109.31 supernatant (3)

[0149] The parameters corresponding to the regression lines obtained for the treatments in Table 5 demonstrate significant differences in the LC.sub.50 values for the spores and crystals mixture, being 2.39-fold more toxic in presence of the supernatant. Purified crystals are significantly more active in absence of spores, suggesting that an adverse effect takes place when inoculated together. However, a synergistic effect is evidenced when the purified crystals are combined with the supernatant, reporting a 28.19-fold more potent treatment when compared to aqueous preparations of spores and crystals mixtures.

[0150] No activity was reported for bacterial preparations containing spores, supernatant or combinations of both.

8.3. Insecticidal Properties of SVBS-1801 Cry Proteins for Neonate Spodoptera frugiperda Larvae

[0151] As commented above, the insecticidal toxicity of a Bt strain is mainly attributed to the delta endotoxins that make up the parasporal crystal. But not all of them show activity or the same degree of activity against a particular insect. Thus, single concentration (100 ng/μl) bioassays were performed in order to determine the activity of single proteins contained in the parasporal crystal, following the same methodology described in Section 8.2. Protein Cry2Ad1 was not included in the assay due to the results obtained in the SDS-PAGE assay of Example 6, which appear to indicate that the protein could not be expressed in the bacterial growing conditions used in Example 1 of the present application.

[0152] Table 6 shows the individual activity of each individual Cry protein when administered at a single concentration of insecticidal protein (100 ng/μl). It demonstrates that out of five proteins the insecticidal activity of the parasporal crystal should be attributed to Cry1Da3, Cry1Ea7 and Cry1Ja1-like, due to the lack of activity of Cry1Ab1 and Cry1Nb1 for newly hatched S. frugiperda larvae.

TABLE-US-00006 TABLE 6 Toxicity of individual proteins for newly hatched larvae of S. frugiperda. Recombinant Protein Toxic/Not toxic (100 ng/μl) Cry1Ab24-like Not toxic Cry1Da3 Toxic Cry1Ea7 Toxic Cry1Ja1-like Toxic Cry1Nb1 Not toxic

[0153] Subsequently, toxic proteins were further evaluated and mean lethal concentrations (LC.sub.50) were estimated. Finally, protein interactions were evaluated by testing a mixture containing equimolar concentrations of the previous recombinant proteins.

[0154] Table 7 shows the parameters corresponding to the regression lines obtained for the three reported toxic proteins (Cry1Da3, Cry1Ea7 and Cry1Ja1-like) when evaluated individually and in an equimolar mixture containing all three in the same ratio.

TABLE-US-00007 TABLE 7 Insecticidal potency of three individual proteins (Cry1Da, Cry1Ea and Cry1Ja-like) and an artificial equimolar mixture containing all three in the ratio 1:1:1, for S. frugiperda neonate larvae. LC.sub.50 χ.sup.2 Relative 95% F. L. Bt Treatment Slope ± SE Intercept (ng/μl) (df) Potency Lower Upper Cry1Ea7 1.03 ± 0.09 3.53 25.75 20.57  1 — — (3) Cry1Da3 1.69 ± 0.16 4.33 2.48 3.53 10.34 7.24 14.86 (3) Cry1Ja1-like 0.88 ± 0.12 4.56 3.12 4.41 8.25 4.62 14.74 (3) Protein Mixture 1.27 ± 0.17 4.95 1.09 2.93 23.59 15.92 41.96 (1:1:1)

[0155] As can be seen in Table 7, S. frugiperda larvae are very susceptible to Cry1Da3 and Cry1Ja1-like, reporting 10.34- and 8.25-fold more toxic than Cry1Ea7, respectively. The absence of overlap between the fiducial limits (FL) of the relative potencies of Cry1Ea7 clearly indicates that the differences are statistically significant when compared to Cry1Da3 or Cry1Ja-like. When the three proteins were combined in an equimolar mixture the LC.sub.50 value is reduced to 1.09 ng/μl, being significantly more potent when compared to the three individual toxins, suggesting a synergistic effect among them.

[0156] In order to calculate the synergistic factor, the expected mean lethal concentration (LC.sub.50) of the mixture relative to that of the three single proteins on basis of the relative proportion of Cry1Da3 (r.sub.a), Cry1Ea7 (r.sub.a) and Cry1Ja1-like (r.sub.c) in the mixture must be calculated (Tabashnik, 1992) and compared to the obtained LC.sub.50 of the mixture (Table 7).

[00001]$L{C}_{50\left(m\right)}={\left[\frac{r_a}{L{C}_{50\left(a\right)}}+\frac{r_b}{L{C}_{50\left(b\right)}}+\frac{r_c}{L{C}_{50\left(c\right)}}\right]}^{-1}$$L{C}_{50\left(m\right)}={\left[\frac{0.33}{248}+\frac{0.33}{25.75}+\frac{0.33}{312}\right]}^{-1}=3.96\mathrm{ng}\text{/}\mathrm{\mu l}$

A synergistic factor of 3.63 was obtained for the mixture of Cry1Da3, Cry1Ea7 and Cry1Ja1-like for newly hatched S. frugiperda larvae.

Example 9.—Toxicity Assay to Determine the Insecticidal Potency of the SVBS-1801 Strain Relative to the Commercial Strains of Dipel (ABTS-351) and XenTari (ABTS-1875) in S. frugiperda Second Instar Larvae

9.1. Procedure for Obtaining SVBS-1801 Active Ingredient (AI)

[0157] The procedure for obtaining SVBS-1801 active ingredients was as set forth in Example 7.

9.2. Preparation of Active Ingredients from Bt Strains of Commercial Products

[0158] In order to compare the activity of the active ingredients prepared from SVBS-1801 strain and Bt strains that give rise to commercial products (ABTS-351 in the case of Dipel®, ABTS-1857 in the case of (XenTari®), the B. thuringiensis strains ABTS-351 and ABTS-1857 were directly isolated from the commercial products DiPel® DF (Kenogard, Valent BioScience Corporation; manufacturing batch 261-355-PG; date of manufacture 01/2016) and XenTari GD (Kenogard, Valent BioScience Corporation; manufacturing batch 264-637-PG; date of manufacture 04/2016), respectively, sold in the European Union. Each bacterial strain was grown at 28° C. for 72 h in sterile CCY medium (Stewart et al., 1981) and the process explained in Example 5 was also follow for these strains, until a slurry with a solid content of 12-15% was obtained for any of the strains, what was considered to be the AI to be compared with the AI obtained from strain SVBS-1801.

9.3. Toxicity Assay by the Droplet Feeding Method using Crystal and Spore Mixtures from the ABTS-351 (Dipel®), ABTS-1857 (XenTari®) and SVBS-1801 Strains in S. frugiperda Second Instar Larvae

[0159] In order to perform the toxicity assay, the following materials are required: 28 well blisters, artificial diet (see section 8.1) and S. frugiperda newly molted second instar larvae. The mixture of crystals and spores should be diluted five times using a dilution factor between 3 and 5, which will result in 6 different concentrations for the AI to be tested in the next step. Likewise, a negative control lacking the AI but preserving the rest of the components shall be prepared. S. frugiperda newly molted second instar larvae are fed drops of one of the 6 different concentrations of the AI, following the droplet feeding method (Hughes and Wood, 1981). Fed larvae were placed in individual wells from a 28-well blister containing 1.5 cm.sup.3 of artificial diet.

[0160] For this study, a total of 28 newly molted second instar larvae were treated with each protein concentration and a range of five concentrations were used for each Bt strain. The bioassay was performed three times. Control insects were fed artificial diet without toxin. The multiwell plates were incubated at 25° C., 60% R.H., and a 14 h/10 h (light/dark) photoperiod. Mortality was recorded after 6 days. Concentration-mortality data were subjected to probit regression analysis (Finney, 1971) in the POLO-PC program (LeOra Software, 1987).

[0161] The results of the concentration-mortality responses obtained with the three Bt strains ABTS-351, isolated from Dipel®, ABTS-1857, isolated from XenTari®, and SVBS-1801 in second-instar S. frugiperda larvae are shown in Tables 8, 9, and 10. The slopes of the fitted regression lines for the three Bt isolates ranged from 0.51 for ABTS-351 to 1.47 for SVBS-1801. The values of the slopes were sufficiently different to not allow adjusting the three regression lines in parallel, with a common slope. Therefore, to estimate the relative potencies, among the three Bt strains, it was necessary to compare the regression lines two by two.

[0162] Table 8 shows the parameters corresponding to the regression lines obtained for Bt strains ABTS-351, isolated from Dipel® and ABTS-1857, isolated from XenTari®. In Table 4, it can be seen that strain ABTS-1857 is 217.2 times more potent than strain ABTS-351 on S. frugiperda second instar. The absence of overlap between the fiducial limits (FL) of the relative potencies of both strains clearly indicate that the differences observed are statistically significant.

TABLE-US-00008 TABLE 8 LC.sub.50 values and relative potencies of ABTS-1857 respect to ABTS-351 on Spodoptera frugiperda second instars. LC.sub.50 χ.sup.2 Relative 95% F. L. Bt strain Slope ± SE Intercept ± SE (μg/ml) (df) Potency Lower Upper ABTS-351 0.51 ± 0.2 2.74 ± 0.3 26,260.0 2.96 1 — — (3) ABTS-1857 0.96 ± 0.1 3.01 ± 0.2 120.9 1.09 217.2 5.5 8,635.9 (4)

[0163] Table 9 shows the parameters corresponding to the regression lines obtained for Bt strains ABTS-351, isolated from Dipel®, and SVBS-1801. Table 9 reflects that strain SVBS-1801 is 1,235.4 times more potent than strain ABTS-351 on S. frugiperda second instar larvae. The absence of overlap between the fiducial limits (FL) of the relative potencies of both strains clearly indicates that the observed differences are statistically significant.

TABLE-US-00009 TABLE 9 LC.sub.50 values and relative potencies of SVBS-1801 respect to ABTS-351 on Spodoptera frugiperda second instars. LC.sub.50 χ.sup.2 Relative 95% F L Bt strain Slope ± SE Intercept ± SE (μg/ml) (df) Potency Lower Upper ABTS-351 0.51 ± 0.2 2.74 ± 0.3  26,260.0 2.96 1 — — (3) SVBS-1801 1.47 ± 0.1 3.05 ± 0.13 21.3 3.14 1,235.4 31.3 48,708.5 (3)

[0164] Table 10 shows the parameters corresponding to the regression lines obtained for Bt strains ABTS-1857, isolated from XenTari® and SVBS-1801. SVBS-1801 is 5.7 times more potent than ABTS-351 on S. frugiperda second instar larvae. The absence of overlap between the fiducial limits (FL) of the relative potencies of both strains clearly indicates that the differences are statistically significant.

TABLE-US-00010 TABLE 10 LC.sub.50 values and relative potencies of SVBS-1801 compared to ABTS-1857 on Spodoptera frugiperda second instars. LC.sub.50 χ.sup.2 Relative 95% F L Bt strain Slope ± SE Intercept ± SE (μg/ml) (df) Potency Lower Upper ABTS-1857 0.96 ± 0.15 3.01 ± 0.15 120.9 1.09 1 — — (3) SVBS-1801 1.47 ± 0.1  3.05 ± 0.13 21.3 3.14 5.7 4.1 7.9 (3)

Example 10.—Insecticidal Potency of the SVBS-1801 Active Ingredient Relative to that of ABTS-351 (Dipen®) and ABTS-1857 (XenTari®) for S. frugiperda Second Instar Larvae

[0165] As indicated in Example 9.3, the toxicity of ABTS-351 (Dipel®), ABTS-1857 (XenTari®) and SVBS-1801 AI was assessed by the droplet feeding method (Hughes and Wood, 1981). ABTS-351 (B. thuringiensis ser. kurstaki) is widely accepted as an international reference for several lepidopteran species and constitutes the AI of commercial products such as Dipel® 2× (Abbot). Likewise, ABTS-1857 (isolated from XenTar®) is often found as a reference AI in bioassays aimed at testing insecticidal potency of products against lepidopterans from the genus Spodoptera.

[0166] The potency of SVBS-1801 insecticidal proteins relative to those of ABTS-351 (Dipel®) and ABTS-1857 (XenTari®) was calculated with regard to the potency (reference potency) indicated in the label of the commercial product used as reference as described by Dulmage (1981).

[00002]$\mathrm{Formula}:\frac{\mathrm{reference}{\mathrm{LC}}_{50}}{\mathrm{sample}{\mathrm{LC}}_{50}}\times \mathrm{reference}\mathrm{potency}\left(\mathrm{IU}\text{/}\mathrm{mg}\right)=\mathrm{sample}\mathrm{potency}\left(\mathrm{IU}\text{/}\mathrm{mg}\right)$$\mathrm{IU}:\mathrm{international}\mathrm{units}$$\mathrm{SVBS}\text{-}1801\mathrm{potency}\mathrm{relative}\mathrm{to}\mathrm{ABTS}\text{-}351\left({\mathrm{Dipel}}^{\circledR }\right):{\mathrm{Dipel}}^{\circledR }\mathrm{potency}\mathrm{resulted}\mathrm{in}32,000\mathrm{IU}\text{/}\mathrm{mg}$$\frac{26,260.0\mathrm{ng}\text{/}\mathrm{\mu l}}{21.3\mathrm{ng}\text{/}\mathrm{\mu l}}\times 32,000\left(\mathrm{IU}\text{/}\mathrm{mg}\right)=39,452,643\left(\mathrm{IU}\text{/}\mathrm{mg}\right)$$\mathrm{SVBS}\text{-}1801\mathrm{potency}\mathrm{relative}\mathrm{to}\mathrm{ABTS}\text{-}1857\left({\mathrm{Xentari}}^{\circledR }\right):{\mathrm{Xentari}}^{\circledR }\mathrm{potency}\mathrm{resulted}\mathrm{in}15,000\mathrm{IU}\text{/}\mathrm{mg}:\frac{120.9\mathrm{ng}\text{/}\mathrm{\mu l}}{21.3\mathrm{ng}\text{/}\mathrm{\mu l}}\times 15,000\left(\mathrm{IU}\text{/}\mathrm{mg}\right)=85,141\left(\mathrm{IU}\text{/}\mathrm{mg}\right)$

Example 11.—Insecticidal Efficacy of SVBS-1801 Relative to HD1 and ABTS-1857 (Xentari®) on S. frugiperda Second Instar Larvae in Semi-Field Maize Plants

[0167] Maize plants in the phenological stage V3 (with 5-6 sheets and 30-35 cm height) were infested with S. frugiperda eggs (150 eggs/plant) that were ready to hatch within 24 h. Once the larvae emerged, they were monitored until they reached second instar. Next, plants were treated with a mixture of crystals and spores (at a concentration of crystals and spores corresponding to 100 mg/L for ABTS-1857 and SVBS-1801 strains). Applications were made using a compressed-air hand sprayer (Matabi 7®, Antzuola, Guipuzcoa, Spain) and they included 0.05% Agral wetter-sticker. 10 ml of spray treatment to run off, which is equivalent to the standard volume of spray application used in maize crops in the region (around 1000 liters/Ha)

[0168] Twenty-eight S. frugiperda larvae were randomly collected by hand from plants in each plot at 20, 30 and 40 hours after application, and reared in the laboratory in 25 ml plastic cups with artificial diet at 25° C. until death or pupation. Mortality was registered daily. Percentage mortality was calculated for each treatment, normalized by arcsine transformation and subjected to repeat measures analysis of variance (ANOVA) in SPSS ver. 12.0 (SPSS, Chicago, Ill.). The characteristics of the variance-covariance matrix were examined for this and all subsequent multivariate analyses by applying Mauchly's sphericity test. The results are summarized in FIG. 8.

Deposit of Biological Material

[0169] Strain SVBS-1801, has been deposited in the Colección Española de Cultivos Tipo (CECT) (Parque Científico de la Universidad de Valencia; calle Catedrático Agustín Escardino, 9; 46980 Paterna, Valencia, Spain) which accepts bacterial strain deposits according to Royal Decree 664/1997 of 12 May 1997. SVBS-1801 has been deposited for patent purposes following the Budapest Treaty guidelines.

[0170] The original deposit receipt (BP/4) and the Viability Certificate (BP/9) of such strain reflect the following relevant data: [0171] final deposit date: 8 Nov. 2018, [0172] strain reference number (accession number): CECT 9753. [0173] Depositor: Serena Valley Biological Systems S.L. (Paseo Universidad 49, 31192 Mutilva, Navarra, Spain). The depositor is different from the applicant.

REFERENCES

[0174] Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) “Basic local alignment search tool.” J. Mol. Biol. 215:403-410.

[0175] Baig, D. N., Bukhari, D. A., and Shakoori, A. R. (2010) cry Genes profiling and the toxicity of isolates of Bacillus thuringiensis from soil samples against American bollworm, Helicoverpa armigera. J. Appl. Microbial., 109, 1967-1978.

[0176] Barretto, M. R. et al. (1999). Insecticidal activity of culture supernatants from Bacillus thuringiensis Berliner strains against Spodoptera frugiperda Smith (Lepidoptera. Noctuidae) Larvae”, An. Soc. Entomol. Brasil, 28: 675-685

[0177] Bradford, M. M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254

[0178] Capalbo D. et al. (2001) Solid-state fermentation of Bacillus thuringiensis tolworthi to control fall armyworm in maize, EJB Electronic Journal of Biotechnology 4(2): 717-3458

[0179] Carozzi, N. B., Kramer, V. C., Warren, G. W., Evola, S., and Koziel, M. G. (1991) Prediction of insecticidal activity of Bacillus thuringiensis strains by polymerase chain reaction product profiles. Appl. Environ. Microbial., 57, 3057-3061.

[0180] Cerón, J., Ortiz, A., Quintero, R., Güereca, I., and Bravo, A. (1995) Specific PCR primers directed to identify <i>cryI<i> and <i>cryIII<i> genes within a <i> Bacillus thuringiensis <i> strain collection. Appl. Envir. Microbial., 61, 3826-3831.

[0181] Crickmore, N., Baum, J., Bravo, A., Lereclus, D., Narva, K., Sampson, K., et al. (2018) Bacillus thuringiensis toxin nomenclature.

[0182] Crickmore, N., Zeigler, D. R., Feitelson, J., Schnepf, E., Van Rie, J., Lereclus, D., et al. (1998) Revision of the nomenclature for the Bacillus thuringiensis pesticidal crystal proteins. Microbial. Mol. Biol. Rev., 62, 807-13.

[0183] Cucarella, C., Solano, C., Valle, J., Amorena, B., Lasa, I., and Penadés, J. (2001) Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J. Bacteria, 183, 2888-2896.

[0184] Donovan, W. P., Engleman, J. T., Donovan, J. C., Baum, J. A., Bunkers, G. J., Chi, D. J., et al. (2006) Discovery and characterization of Sip1A: a novel secreted protein from Bacillus thuringiensis with activity against coleopteran larvae. Appl. Microbial. Biotechnol., 72, 713-719.

[0185] Dulmage, H. T. (1981) Insecticidal activity of isolated of Bacillus thuringiensis and their potential for pest control. Microb. Control pests plant Dis., 1970-1980, Ed. H.D Burges, Academic Press, London.

[0186] Estruch, J. J., Warren, G. W., Mullins, M. A., Nye, G. J., Craig, J. A., and Koziel, M. G. (1996) Vip3A, a novel Bacillus thuringiensis vegetative insecticidal protein with a wide spectrum of activities against lepidopteran insects. Proc. Natl. Acad. Sci., 93, 5389-5394.

[0187] Ferrandis, M. D., Júrez-Pérez, V. M., Frutos, R., Bel, Y., and Ferré, J. (1999) Distribution of cryI, cryII and cryV genes within Bacillus thuringiensis isolates from Spain. Syst. Appl. Microbial., 22, 179-185.

[0188] Finney, D. (1971) Probit analysis. 3rd Ed. Cambridge Univ. Press, 333.

[0189] Frankenhuyzen, K. van (2009) Insecticidal activity of Bacillus thuringiensis crystal proteins. J. Invertebr. Pathol., 101, 1-16.

[0190] Hernández, C. S., Martinez, C., Porcar, M., Caballero, P., and Ferré, J. (2003) Correlation between serovars of Bacillus thuringiensis and type I β-exotoxin production. J. Invertebr. Pathol., 82, 57-62.

[0191] Hilbeck A. and Otto M. 2015. “Specifity and combinatorial effects of Bacillus thuringiensis Cry toxins in . . . ”. Frontiers in Environmental Science, Review published on 9 Nov. 2015

[0192] Hoffman, D. J. and Lawson, F. R. (1964) Preliminary Studies on Mass Rearing of the Tobacco Hornworm. J. Econ. Entomol., 57, 354-355.

[0193] Hu, Y., Platzer, E. G., Bellier, A., and Aroian, R. V. (2010) Discovery of a highly synergistic anthelmintic combination that shows mutual hypersusceptibility. Proc. Natl. Acad. Sci., 107, 5955-5960.

[0194] Hughes, P. R. and Wood, H. A. (1981) A synchronous peroral technique for the bioassay of insect viruses. J. Invertebr. Pathol., 37, 154-159.

[0195] Iriarte, J., Bel, Y., Ferrandis, M. D., Andrew, R., Murillo, J., Ferré, J., and Caballero, P. (1998) Environmental Distribution and Diversity of Bacillus thuringiensis in Spain. Syst. Appl. Microbiol., 21, 97-106.

[0196] Laemmli, U. K. (1970) Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature, 227, 680-685.

[0197] Lecadet, M.-M., Frachon, E., Dumanoir, V. C., Ripouteau, H., Hamon, S., Laurent, P., and Thiery, I. (1999) Updating the H-antigen classification of Bacillus thuringiensis. J. Appl. Microbiol., 86, 660-672.

[0198] LeOra Software (1987) LeOra Software (1987) POLO PC, a User Guide to Probit or Logit Analysis. Le Ora Software, Berkelay, Calif., USA.

[0199] Li, L., Yang, C., Liu, Z., Li, F., and Yu, Z. (2000) [Screening of acrystalliferous mutants from Bacillus thuringiensis and their transformation properties]. Wei Sheng Wu Xue Bao, 40, 85-90.

[0200] López-Pazos, S. A., Rojas Arias, A. C., Ospina, S. A., and Cerón, J. (2010) Activity of Bacillus thuringiensis hybrid protein against a lepidopteran and a coleopteran pest. FEMS Microbiol. Lett., 302, 93-98.

[0201] Masson, L., Erlandson, M., Puzstai-Carey, M., Brousseau, R., Juárez-Pérez, V., and Frutos, R. (1998) A holistic approach for determining the entomopathogenic potential of Bacillus thuringiensis strains. Appl. Environ. Microbiol., 64, 4782-8.

[0202] Milner, R. J. (1994) History of Bacillus thuringiensis. Agric. Ecosyst. Environ., 49, 9-13.

[0203] Mounsef J R, Salameh D, Awad M kallassy, Chamy L, Brandam C, Lteif R. 2014. A simple method for the separation of Bacillus thuringiensis spores and crystals. J Microbiol Methods 107:147-149

[0204] Ohba, M., Mizuki, E., and Uemori, A. (2009) Parasporin, a new anticancer protein group from Bacillus thuringiensis. Anticancer Res., 29, 427-33.

[0205] Park, H. W., Ge, B., Bauer, L. S., and Federici, B. A. (1998) Optimization of Cry3A yields in Bacillus thuringiensis by use of sporulation-dependent promoters in combination with the STAB-SD mRNA sequence. Appl. Environ. Microbiol., 64, 3932-8.

[0206] Polanczyk, R. A. et al. (2000) Effectiveness of Bacillus thuringiensis strains against Spodoptera frugiperda (lepidopera: noctuidae)”. Brazilian Journal of Microbiology, 31: 165-167.

[0207] Roh, J. Y., Kim, Y. S., Wang, Y., Liu, Q., Tao, X., Xu, H. G., et al. (2010) Expression of Bacillus thuringiensis mosquitocidal toxin in an antimicrobial Bacillus brevis strain. J. Asia. Pac. Entomol., 13, 61-64.

[0208] Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press.

[0209] Schnepf, H. E. and Whiteley, H. R. (1981) Cloning and expression of the Bacillus thuringiensis crystal protein gene in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A., 78, 2893-7.

[0210] S̆ebesta, K. and Horská, K. (1970) Mechanism of inhibition of DNA-dependent RNA polymerase by exotoxin of Bacillus thuringiensis. Biochim. Biophys. Acta—Nucleic Acids Protein Synth., 209, 357-367.

[0211] Shah, S. H., Jan, S. A., Ahmad, N., Khan, S. U., Kumar, T., Iqbal, A., et al. (2015) Use of Different Promoters in Transgenic Plant Development: Current Challenges and Future Perspectives. Am. J. Agric. Environ. Sci., 15, 664-675.

[0212] Sharma, H. C., Dhillon, M. K., and Arora, R. (2008) Effects of Bacillus thuringiensis δ-endotoxin-fed Helicoverpa armigera on the survival and development of the parasitoid Campoletis chlorideae. Entomol. Exp. Appl., 126, 1-8.

[0213] Stewart, G. S., Johnstone, K., Hagelberg, E., and Ellar, D. J. (1981) Commitment of bacterial spores to germinate A measure of the trigger reaction. Biochem. J., 198, 101-106.

[0214] Tabashnik, B. E. (1992) Evaluation of synergism among Bacillus thuringiensis toxins. Appl. Environ. Microbiol., 58, 3343-3346.

[0215] Thomas, W. E. and Ellar, D. J. (1983) Bacillus thuringiensis var israelensis crystal delta-endotoxin: effects on insect and mammalian cells in vitro and in vivo. J. Cell Sci., 60, 181-97.